Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders??? Equity

v3.24.1
Consolidated Statements of Shareholders’ Equity - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   886,860    
Beginning balance at Dec. 31, 2021 $ 72,770 $ 0 $ 187,510 $ (114,740)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, gross (in shares)   499,826    
Issuance of common shares, gross $ 27,686   27,686  
Issuance of common shares upon vesting of RSUs (in shares)   12,584    
Stock option exercise (in shares) 5,296 5,056    
Stock option exercise $ 22   22  
Share-based compensation expense 2,343   2,343  
Beneficial conversion feature of Convertible Note 1,750   1,750  
Conversions of Convertible Note to common shares (in shares)   50,233    
Conversions of Convertible Note to common shares 3,363   3,363  
Equity issuance costs (1,361)   (1,361)  
Net Loss $ (66,165)     (66,165)
Ending balance (in shares) at Dec. 31, 2022 1,454,559 1,454,559    
Ending balance at Dec. 31, 2022 $ 40,408 $ 0 221,313 (180,905)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, gross (in shares)   253,898    
Issuance of common shares, gross 1,339   1,339  
Issuance of common shares upon vesting of RSUs (in shares)   19,540    
Cancellation of shares (in shares)   (312)    
Cancellation of shares (250)   (250)  
Share-based compensation expense 818   818  
Equity issuance costs (199)   (199)  
Net Loss $ (17,899)     (17,899)
Round off due to reverse split (in shares)   13    
Ending balance (in shares) at Dec. 31, 2023 1,727,698 1,727,698    
Ending balance at Dec. 31, 2023 $ 24,217 $ 0 $ 223,021 $ (198,804)